

AMENDMENTS TO THE CLAIMS

The listing of claims provided below will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1 - 16. (cancelled)

17. (Currently amended) A therapeutic composition for promoting wound healing, comprising effective amounts of:

(i) microparticles prepared by a process comprising:

collecting thrombocytes;

activating the thrombocytes by administration of an activating agent selected from the group consisting of thrombin, collagen, calcium ionophore A23187 and C5b-9, such that microparticles are released from the thrombocytes into a liquid medium; and

~~collecting~~ separating the microparticles from the liquid medium by a method selected from the group consisting of differential centrifugation, filtration and affinity chromatography and ; and

(ii) one or more added extracellular matrix material.

18. (previously presented) The therapeutic composition of claim 17, wherein the extracellular matrix material is selected from the group consisting of fibrin, fibrinogen, fibronectin, coagulation Factor XIII, collagen, polyactone, and calcium phosphate.

19. (previously presented) The therapeutic composition of claim 17, which has been subjected to a procedure selected from the group consisting of virus inactivation and virus depletion.

20. (previously presented) The therapeutic composition of claim 18, which has been subjected to a procedure selected from the group consisting of virus inactivation and virus depletion.

21. (currently amended) A drug product comprising:

(a) a therapeutic composition comprising effective amounts of:

(i) microparticles prepared by a process comprising:

collecting thrombocytes;

activating the thrombocytes by administration of an activating agent selected from the group consisting of thrombin, collagen, calcium ionophore A23187 and C5b-9, such that microparticles are released from the thrombocytes into a liquid medium; and

~~collecting~~ separating the microparticles from the liquid medium by a method selected from the group consisting of differential centrifugation, filtration and affinity chromatography; and

(ii) one or more added extracellular matrix material;

(b) a biocompatible material.

22. (previously presented) The drug product of claim 21, wherein the biocompatible material is selected from the group consisting of titanium and apatite.

23. (previously presented) A metal surface to which the therapeutic composition of claim 17 is applied.

24. (previously presented) A metal surface to which the therapeutic composition of claim 18 is applied.

25. (previously presented) A metal surface to which the therapeutic composition of claim 19 is applied.

26. (previously presented) A metal surface to which the therapeutic composition of claim 20 is applied.